DBV Technologies S.A. 8-K

What Happened

• DBV Technologies announced that its Board approved a 2026 Performance Share Unit Plan and, effective May 5, 2026 (grant date), granted CEO Daniel Tassé 1,740,000 performance share units (PSUs).
• Vesting of the PSUs is tied to FDA acceptance for review of Biologics License Applications (BLAs) for Viaskin Peanut: 870,000 PSUs for ages 4–7 and 870,000 PSUs for ages 1–3. If a single BLA covers both groups, the condition is treated as satisfied in full.

Key Details

• Approval and grant: Board approved plan April 30, 2026; grant date May 5, 2026; Plan implemented under shareholder authorization from the June 11, 2025 AGM.
• Performance and timing: PSUs vest only if performance conditions are met by July 1, 2028 (the Vesting Date); otherwise they are cancelled.
• Delivery schedule: Vested shares to be delivered in four installments (July 1, 2028; Jan 1, 2029; July 1, 2029; Jan 1, 2030). Vested shares are freely transferable.
• Continued employment: Vesting also requires Mr. Tassé to remain employed as CEO through the vesting period, with limited exceptions (death, disability, qualifying retirement, termination without cause or for good reason). Change in control will deem performance conditions met but continued employment condition still applies.
• Tax and payment rules: If required under Section 409A and the CEO is a “specified employee,” certain payments may be delayed six months; Board may substitute cash for shares for non-French tax residents.

Why It Matters

• This grant ties a large portion of the CEO’s compensation directly to FDA regulatory milestones for Viaskin Peanut, aligning leadership incentives with key clinical/regulatory outcomes that can affect the company’s valuation.
• If the FDA accepts/reviews the BLAs and PSUs vest, delivery of up to 1.74 million shares will dilute existing shareholders to some degree; the timing and value depend on achievement of the FDA milestones and the share price at delivery.
• The continued-employment requirement and delayed payment rules protect shareholders by linking payout to ongoing leadership and regulatory progress, while change-in-control and retirement/termination provisions define limited exceptions.